Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01537497 | A Study To Evaluate The Effects Of PF-05175157 In Healthy Volunteers | PHASE1 | COMPLETED | 31 | — | — | Mar 1, 2012 | May 1, 2012 | Jul 10, 2012 | 1 | United States |
| NCT01433380 | A Study To Evaluate PF-05175157 In Healthy Volunteers | PHASE1 | COMPLETED | 22 | — | — | Jul 1, 2011 | May 1, 2012 | May 18, 2012 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 100 mg PF-05175157 | EXPERIMENTAL | The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized. |
| 250 mg PF-05175157 | EXPERIMENTAL | The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized. |
| 600 mg PF-05175157 | EXPERIMENTAL | The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized. |
| Placebo | PLACEBO_COMPARATOR | The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized. |
| Name | Type | Description |
|---|---|---|
| PF-05175157 | DRUG | One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM. |
| Placebo | DRUG | One single oral dose of placebo will be administered as a powder-in-capsule in the fasting state in the AM. |
Inclusion Criteria: * Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive. * Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead EC...